Aethlon Medical to Publish Long COVID Study on November 20, 2025
Aethlon Medical announced the 20 November 2025 publication of a pre-clinical study in the pre-print online archive bioRxiv, simultaneously been submitted for consideration to a peer-reviewed journal. Long COVID refers to persistent symptoms following acute COVID-19 infection. These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain, and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the U.S. alone with symptoms lasting a year. No treatment has proven effective. Extracellular vesicles, or EVs, nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. Aethlon Medical's Hemopurifier is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin, or GNA, previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs and decrease microRNAs in a patient with severe acute COVID-19 infection. Plasma of those with Long COVID contained elevated levels of both large and small EVs. Removal of small EVs by the GNA affinity resin correlated with mannose positive large EVs indicating the same glycan target for removal by the Hemopurifier was present in both populations.
Get Free Real-Time Notifications for Any Stock
Analyst Views on AEMD
About AEMD
About the author
Aethlon Medical Secures $3.3 Million Financing to Accelerate Cancer Treatment
- Financing Agreement: Aethlon Medical has entered into a securities purchase agreement with a single institutional investor to sell 595,897 shares and warrants for 1,042,820 shares, raising approximately $3.3 million, expected to close on December 8, 2025, enhancing liquidity for R&D support.
- Warrant Inducement: The company has negotiated a warrant inducement agreement to lower the exercise price of March and September 2025 warrants to $4.03, which is expected to encourage the investor to exercise these warrants, providing additional funding for the company.
- Market Compliance: This financing adheres to Nasdaq rules under Section 4(a)(2) of the Securities Act, ensuring the company's compliance in capital markets, which enhances investor confidence and improves the company's reputation.
- Future Growth Potential: Aethlon is focused on developing the Hemopurifier to address unmet needs in oncology and infectious diseases, and this financing will accelerate clinical trial processes, boosting the company's competitiveness in the medical device sector.
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading
American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.
Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).
Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.
Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.
